Abstract: PURPOSE: To observe the effect of recombinant human basic fibroblast growth factor (bFGF) atomization inhalation on postoperative sore throat following oral and maxillofacial operation under general anethesia. METHODS: Forty patients in whom oral and maxillofacial operation trachea was removed under general anesthesia were randomly divided into treatment and control groups; the treatment group received bFGF 35000IU + normal saline 20 mL, compression inhalation, day 1, every 20min, continued for 3 d; the control group was given normal saline 5 mL + dexamethasone 5 mg + gentamicin 80000 U + chymotrypsin 4000 U, compression inhalation, twice a day, every 20 min, continued for 3 d. Occurrence of postoperative sore throat 12 h after operation was recorded and visual analog scale (VAS) of sore throat (swallowing) 12,24,48,72 h after operation was measured. SPSS l4.0 software package was used for statistical analysis. RESULTS: The incidence of sore throat in the treatment group was significantly lower than that in the control group (P<0.01) 12 h after operation; sore throat (swallowing) VAS 12,24,48 and 72 h after operation in the treatment group were significantly lower than that in the control group (P<0.05). CONCLUSIONS: bFGF atomization inhalation can reduce the incidence of sore throat and sore throat level in oral and maxillofacial surgery after endotracheal intubation.

Key words: General anesthesia, Postoperative sore throat, Trachea cannula